A systematic review and meta-analysis of prospective studies found that elevated levels of interleukin-6 (IL-6) and C-reactive protein (CRP) are significantly associated with an increased risk of type 2 diabetes. The meta-analysis included 10 studies for IL-6 and 22 cohorts for CRP, with a total of 19,709 participants and 4,480 cases for IL-6, and 40,735 participants and 5,753 cases for CRP. The results showed a significant dose-response relationship between IL-6 levels and type 2 diabetes risk (relative risk [RR] 1.31 [95% CI 1.17–1.46]) and between CRP levels and type 2 diabetes risk (RR 1.26 [1.16–1.37]). The associations were consistent across most subgroups, including by geographic region, sex, and study quality. However, some studies suggested that IL-6 did not predict diabetes risk in Aboriginal populations. The study also found that while CRP was significantly associated with diabetes risk, the association was slightly attenuated when adjusted for glycemia or waist circumference/waist-to-hip ratio. The findings support the hypothesis that chronic inflammation is a predictor of type 2 diabetes development. The study highlights the potential of inflammatory markers like IL-6 and CRP as targets for lifestyle and therapeutic interventions in the prevention and management of type 2 diabetes. However, the study acknowledges limitations, including variations in diabetes diagnosis methods and potential confounding factors. The results suggest that inflammation plays a crucial role in the pathogenesis of type 2 diabetes, and further research is needed to confirm these findings in specific populations.A systematic review and meta-analysis of prospective studies found that elevated levels of interleukin-6 (IL-6) and C-reactive protein (CRP) are significantly associated with an increased risk of type 2 diabetes. The meta-analysis included 10 studies for IL-6 and 22 cohorts for CRP, with a total of 19,709 participants and 4,480 cases for IL-6, and 40,735 participants and 5,753 cases for CRP. The results showed a significant dose-response relationship between IL-6 levels and type 2 diabetes risk (relative risk [RR] 1.31 [95% CI 1.17–1.46]) and between CRP levels and type 2 diabetes risk (RR 1.26 [1.16–1.37]). The associations were consistent across most subgroups, including by geographic region, sex, and study quality. However, some studies suggested that IL-6 did not predict diabetes risk in Aboriginal populations. The study also found that while CRP was significantly associated with diabetes risk, the association was slightly attenuated when adjusted for glycemia or waist circumference/waist-to-hip ratio. The findings support the hypothesis that chronic inflammation is a predictor of type 2 diabetes development. The study highlights the potential of inflammatory markers like IL-6 and CRP as targets for lifestyle and therapeutic interventions in the prevention and management of type 2 diabetes. However, the study acknowledges limitations, including variations in diabetes diagnosis methods and potential confounding factors. The results suggest that inflammation plays a crucial role in the pathogenesis of type 2 diabetes, and further research is needed to confirm these findings in specific populations.